Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074425 · ClinicalTrials.gov registry record · Phase 2
BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 3,101
- Enrollment target
NCT00074425: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00074425 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3,101 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2232% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00074425, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3,101 participants
- Enrollment target
Study Summary
The majority of HIV infected people worldwide became infected with the virus through heterosexual contact. BufferGel and PRO 2000 Gel are vaginal gels designed to prevent women from becoming infected with HIV during sexual intercourse with an HIV infected partner. This study will test the safety and effectiveness of these gels.
Interventions
- DRUG Placebo gel
- DRUG BufferGel
- DRUG PRO 2000/5 Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,101 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
What the finished NCT00074425 record still lists
NCT00074425 is an interventional study that assigns participants to a tested intervention. Its 3,101 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2232% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo gel is the first listed.
NCT00074425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00074425 about?
NCT00074425 is a clinical study titled "BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women". The majority of HIV infected people worldwide became infected with the virus through heterosexual contact. BufferGel and PRO 2000 Gel are vaginal gels designed to prevent women from becoming infected with HIV during sexual intercourse with an HIV infected partner. This study will test the safety and...
What is the current status of trial NCT00074425?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3,101 participants. The study started on 2005-01. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00074425?
The interventions under investigation include: Placebo gel (DRUG), BufferGel (DRUG), PRO 2000/5 Gel (DRUG).
Who is sponsoring clinical trial NCT00074425?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00074425's enrollment target sits among peer trials
3,101 6th of 2000 higher than 1,995 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
- NCT05051722 · 3,110 participants
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia